Advanced RCC: nivolumab shows benefit even after progression

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • 13% of patients with advanced renal cell carcinoma (aRCC) treated beyond progression (TBP) with nivolumab (Opdivo) experiencing ≥30% further decrease in tumor burden.
  • Tumor burden reduction was observed in patients who initially responded and then progressed, and patients with stable ...